Drug Type Monoclonal antibody |
Synonyms humLpMab 23-f |
Target |
Action inhibitors |
Mechanism PDPN inhibitors(podoplanin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | Japan | 20 Oct 2023 | |
| Squamous non-small cell lung cancer | Preclinical | Japan | 20 Oct 2023 |






